News

Technology News

Heron Therapeutics Touts Recent Progress

Monday, August 10, 2015 5:01:00 AM PDT | VentureDeal
   Redwood City, California  --  Biotechnology company Heron Therapeutics (NASDAQ: HRTX) reported second-quarter 2015 financial results and touted its recent "corporate progress".

In July of this year, the company resubmitted an NDA for its SUSTOL injection to help prevent acute and delayed chemotherapy-induced nausea and vomiting.

Heron also initiated two Phase II clinical trials of its HTX-011 candidate for the prevention of post-operative pain.

The company says it has four product candidates in the pipeline, including its HTX-019, a proprietary intravenous formulation of the NK1 receptor antagonist aprepitant for the prevention of chemotherapy induced nausea and vomiting.

Heron reported greater net losses for the three and six months ended June 30, 2015 compared to the same periods in 2014.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1